BioCentury | Dec 13, 2019
Product Development

Leveraging real-world data to assess the promise of CAR Ts, Dutch style

With the next set of expensive CAR T therapies poised to enter the market based on limited datasets, the Netherlands is proactively gathering the evidence it needs to make reimbursement decisions. The Dutch Health Institute...
BioCentury | Jul 21, 2017
Strategy

Accessing miracles

With unanimous backing of an FDA advisory committee, overwhelming efficacy and a robust REMS, all signs suggest Novartis AG ’s tisagenlecleucel-T is headed to the market for children and young adults with a rare leukemia....
BC Extra | May 26, 2017
Company News

Priority Review for Kite's CAR T therapy

Kite Pharma Inc. (NASDAQ:KITE) said FDA accepted and granted Priority Review to a BLA for chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel ( KTE-C19 ) to treat refractory aggressive non-Hodgkin’s lymphoma (NHL). The PDUFA date...
BC Week In Review | Jun 20, 2016
Clinical News

Anti-CD19 chimeric antigen receptor: Updated Phase I data

Data from 22 patients with DLBCL, follicular lymphoma or mantle cell lymphoma (MCL) in an open-label, U.S. Phase I trial showed that a single infusion of anti- CD19 CAR T cells given 2 days after...
BC Week In Review | May 30, 2016
Clinical News

Anti-CD19 chimeric antigen receptor: Phase I data

Data from 19 patients with various subtypes of DLBCL in an NIH-funded Phase I trial showed that a single infusion of anti- CD19 CAR T cells given 2 days after completion of low-dose conditioning chemotherapy...
Items per page:
1 - 5 of 5